PUNE, India, May 24, 2017 /PRNewswire/ --
According to a new market research report "Protein Assays Market by Product (Reagent, Kit, Instruments), Type (Dye Binding, Test Strip), Application (Drug Discovery, Disease Diagnosis), Technology (Colorimetric, Fluorescence), End User (Pharmaceutical, Clinical Lab) - Global Forecasts to 2022", published by MarketsandMarkets™, this report provides a detailed overview of the major drivers, restraints, challenges, opportunities, and strategies impacting the anatomic pathology market, along with revenue estimates & forecasts and market share analysis.
Browse 61 market data tables and 33 figures spread through 126 pages and in-depth TOC on "Protein Assays Market"
Early buyers will receive 10% customization on this report.
The global protein assays market is expected to reach USD 2.41 Billion by 2022 from USD 1.42 Billion in 2017, at a CAGR of 11.1% from 2017 to 2022. The increasing pharmaceutical & biotech R&D expenditure and favorable government funding scenario for proteomics research are the major factors driving the growth of this market. In this report, the global protein assays market is segmented based on type, product, technology, application, end user, and region.
Based on type, the protein assays market is segmented into dye-binding assays, copper-ion-based assays, test strip-based assays, and other protein assays. On the basis of product, the protein assays market is segmented into reagents, kits, and instruments & accessories. In 2017, the reagents segment is expected to account for the largest share of the market. This growth can be attributed to the quick and ready-to-use modifications and the requirement of repeat purchase of reagents.
On the basis of technology, the protein assays market is segmented into absorbance-based protein assays, colorimetric protein assays, and fluorescence-based protein assays. Based on application, the protein assays market is segmented into disease diagnosis, drug discovery & development, and other applications. The drug discovery & development segment is expected to account for the largest market share in 2017. The increase in the R&D expenditure in the life science industry is a key market driver for this segment.
Speak To Analyst: http://www.marketsandmarkets.com/speaktoanalyst.asp?id=93720547
Based on end user, the protein assays market is segmented into pharmaceutical & biotechnology companies, clinical laboratories, hospitals, academic research institutes, and other end users. In 2017, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the market. This growth can be attributed to the increasing drug development in the life science industry.
On the basis of region, the global protein assays market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). Asia is expected to grow at the highest CAGR during the forecast period. The growth in this region is primarily driven by the increasing pharmaceutical and biotechnology R&D expenditure and availability of government funding for life sciences research.
Download PDF Brochure@ http://www.marketsandmarkets.com/pdfdownload.asp?id=93720547
Some of the major players operating in the protein assays market are Thermo Fisher Scientific (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Merck KGaA (Germany), Cell Signaling Technology, Inc. (U.S.), General Electric Company (U.S.), and PerkinElmer Inc. (U.S.).
Browse Related Reports:
Multiplex Assays Market by Product (Consumable (Kits & Reagents, Panels)), Type (Nucleic Acid-Based, Protein-Based), Technology (Pcr, Planar Array), Application (R&D, Companion Diagnostics), End User (Hospital, Clinical Laboratory) - Global Forecast to 2021
Proteomics Market by Instrument, Reagent & Service (Spectroscopy, Chromatography, Electrophoresis, Immunoassay, HPLC, X-Ray Crystallography, Mass Spectrometry and Surface Plasmon Resonance), Application (Diagnostics, Drug Discovery) - Forecast to 2021
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
701 Pike Street
Suite 2175, Seattle,
WA 98101, United States
Visit Our Blog @ http://mnmblog.org/market-research/healthcare/biotechnology
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets